Released May 2, 2018, after the close
10-Q filed May 10, 2018, 40 days after period end · 0001171843-18-003819
Q1 2018 · 10-Q
Revenue$26.76M$26.76M +48.0% vs Q1 2017+23.6% vs Q4 2017
Net Income-$4.06M-$4.06M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.11-$0.11 N/M vs Q1 2017N/M vs Q4 2017
Gross Profit$13,269,000+38.6%
Operating Income-$1,266,000N/M
Operating Cash Flow$448,000N/M
Free Cash Flowderived-$45,000N/M
Margins · derived
Gross margin49.6%−3.4 pt vs Q1 2017
Operating margin-4.7%−2.8 pt vs Q1 2017
Net margin-15.2%−9.3 pt vs Q1 2017
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | $26.76M | $18.09M | $26.96M | $25.76M |
| Net Income | -$4.06M | -$1.07M | -$636.00K | -$1.40M |
| EPS Diluted | -$0.11 | -$0.03 | -$0.02 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR